Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.37 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599701 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599686 | 0.90 | ASAH1 (0.40) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599683 | 0.90 | ASAH1 (0.40) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599134 | 0.89 | ALDH1A1 (0.37) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599876 | 0.88 | ZDHHC2 (0.38) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599871 | 0.88 | ZDHHC2 (0.38) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599724 | 0.79 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL5599303 | 0.73 | MMP2 (0.59) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599307 | 0.73 | MMP2 (0.59) | ALDH1A1ASAH1ACER2HDAC8HDAC3 | |
| SCHEMBL5599660 | 0.73 | MMP2 (0.59) | ALDH1A1ASAH1ACER2HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282605-B2 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | KANEKA CORPORATION (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20060223152-A1 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | KANEKA CORPORATION (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1650187-A1 | OPTICALLY ACTIVE 2-ALLYLCARBOXYLIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223152-A1 | Optically active 2-allylcarboxylic acid derivative and process for producing the same | APEH, NAAA, AADAC | ALDH1A1 353/4885ASAH1 7/4885ACER2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.